Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02656511 · ClinicalTrials.gov registry record · Phase 4

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

A Phase 4 study of HIV, sponsored by University of California, San Francisco.

Active
Registry status
Phase 4
Development phase
74
Enrollment target
1
Study location

NCT02656511: Active Phase 4 study of HIV, sponsored by University of California, San Francisco.

NCT02656511 is a Phase 4 study of HIV that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 74 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02656511, a Phase 4 study of HIV, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection (estimated date of infection within the last 90 days). The primary aim of the study is to evaluate whether initiation of dolutegravir plus emtricitabine/tenofovir during acute/early HIV infection leads to protection of CD4+ T cells and other immune cells in the peripheral blood and lymphoid tissue from infection.

Primary Outcome

The number of grade 2 or higher severity adverse events (AEs) or drug-related laboratory abnormalities that exceed a frequency of 5% over a 6 month study period.

Conditions Studied

Interventions

  • DRUG Dolutegravir
  • DRUG Emtricitabine/Tenofovir

Study Locations (1)

California

  • San Francisco General Hospital - San Francisco

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2015-12
Est. Completion 2028-05
Phase Phase 4

What the registry record for NCT02656511 still lists

NCT02656511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Dolutegravir is the first listed.

NCT02656511 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02656511 about?

NCT02656511 is a clinical study titled "Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection". The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection (estimated date of infection within the last 90 days). The primary aim of the study is to evaluate whether initiation of dolutegravir plus emtri...

What is the current status of trial NCT02656511?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 74 participants. The study started on 2015-12. Estimated completion is 2028-05.

What conditions does trial NCT02656511 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT02656511?

The interventions under investigation include: Dolutegravir (DRUG), Emtricitabine/Tenofovir (DRUG).

Who is sponsoring clinical trial NCT02656511?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02656511 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02656511's enrollment target sits among peer trials

74 188th of 303 higher than 116 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02656511, the US trial registry maintained by the National Library of Medicine. NCT02656511 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.